KURA Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Kura Oncology, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$21.09 |
52 Week High | US$24.17 |
52 Week Low | US$7.41 |
Beta | 0.88 |
11 Month Change | 2.38% |
3 Month Change | 7.33% |
1 Year Change | 111.53% |
33 Year Change | 11.35% |
5 Year Change | 9.39% |
Change since IPO | 40.60% |
Recent News & Updates
Recent updates
Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Jul 12Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
May 08Kura Oncology: Balancing Act Of Promise And Pragmatism
May 07Kura Oncology: Ziftomenib's Path To AML Market Widens
Jan 31Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price
Jan 25Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?
Jan 31Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
Jul 13We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Kura Oncology Investor Presentation - Slideshow
May 08What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?
Dec 14Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
Dec 10Kura Oncology (KURA) Presents At ASH Virtual Investor Event
Dec 08Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate
Dec 07Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow
Nov 17Shareholder Returns
KURA | US Biotechs | US Market | |
---|---|---|---|
7D | 0.7% | 4.2% | -0.6% |
1Y | 111.5% | 15.7% | 17.3% |
Return vs Industry: KURA exceeded the US Biotechs industry which returned 17.1% over the past year.
Return vs Market: KURA exceeded the US Market which returned 17.5% over the past year.
Price Volatility
KURA volatility | |
---|---|
KURA Average Weekly Movement | 6.1% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KURA has not had significant price volatility in the past 3 months.
Volatility Over Time: KURA's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 142 | Troy Wilson | kuraoncology.com |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Kura Oncology, Inc. Fundamentals Summary
KURA fundamental statistics | |
---|---|
Market cap | US$1.58b |
Earnings (TTM) | -US$168.09m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs KURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KURA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$168.09m |
Earnings | -US$168.09m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.21 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 1.9% |
How did KURA perform over the long term?
See historical performance and comparison